In this episode of the Oncology Brothers podcast we navigated the rapidly evolving treatment landscape of Metastatic Hormone Receptor-Positive Breast Cancer. We were joined by Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University, to discuss the implications of new targeted therapies, optimal sequencing strategies, and practical toxicity management.

Listen us on:

Follow us on social media:

•⁠  YouTube: https://www.youtube.com/@oncologybrothers

The discussion covered:

Join us as we break down the latest data and provide actionable insights for the practicing oncologist. Don't forget to subscribe for more episodes in our breast cancer algorithm series!

#MetastaticBreastCancer, #HRPositive, #ADCsequencing, #PIK3CA-AKT, #OncologyPodcast, #OncologyBrothers

In this episode of the Oncology Brothers podcast, hosts Rahul and Rohit Gosain dived deep into the evolving landscape of breast cancer treatment algorithms, focusing on early and locally advanced hormone receptor-positive breast cancer. Joined by Dr. Erica Mayer, a breast medical oncologist at the Dana-Farber Cancer Institute. 

Listen us on:

Follow us on social media:

•⁠  YouTube: https://www.youtube.com/@oncologybrothers/

The discussion covered:

Join us as we explore the latest data, treatment paradigms, and the importance of patient-shared decision-making in breast cancer care. Don't forget to subscribe for more insights and staying up to date in the field of cancer. 

In this episode of the Oncology Brothers podcast, we engaged in a thought-provoking discussion with Dr. Patrick Soon-Shiong, a pioneer in oncology and the innovator behind the approval of nab-paclitaxel (Abraxane). We delved into the exciting potential of Anktiva (N-803), an IL-15 receptor super agonist designed to expand and activate natural killer (NK) cells and CD8 T cells, with the hope of revolutionizing cancer treatment.

Dr. Soon-Shiong shared insights into the mechanism of action of Anktiva, its current approvals in non-muscle invasive bladder cancer, and extended approval in non-small cell lung cancer in Saudi Arabia, and the promising clinical trial data that suggests a significant increase in overall survival for patients. The conversation also touched on the importance of restoring lymphocyte counts and the implications for treating various tumor types.

Join us as we explore the future of immunotherapy, the challenges of regulatory approval, and the potential for Anktiva to change the landscape of cancer treatment.

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more discussions on the latest in oncology!

#Oncology #CancerTreatment #Immunotherapy #IL15Agonist #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56.

Key topics included:

Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients.

Follow us on social media:

 Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!

#HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option.

Episode Highlights:

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management.

Follow us on social media:

Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals!

#AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option.

Episode Highlights:

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management.

Follow us on social media:

Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals!

#AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the current treatment landscape for head and neck cancer. We welcomed Dr. Fangdi Sun, a head and neck medical oncologist from Stanford University, to discuss key topics including:

Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the complexities of head and neck cancer treatment. Don't miss out on this informative discussion!

Follow us on social media:

Subscribe to our channel for more episodes as we continue to bridge the gap in oncology!

In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention.

Key topics discussed included:

Join us for an informative discussion as we bridge the gap between academic research and community practice, helping healthcare professionals and patients navigate the evolving landscape of myeloma treatment.

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, conference highlights, and FDA approvals!

Feeling overwhelmed by the rapid pace of change in multiple myeloma? ASH 2025 delivered potentially practice-changing data that could redefine second-line therapy and beyond.

In this episode, we sat down with myeloma specialist Dr. Ben Derman from the University of Chicago to dissect the most critical studies. We moved from the controversial treatment of high-risk smoldering myeloma to head-to-head comparisons in newly diagnosed disease, and finally, to the groundbreaking bispecific antibody data that is set to revolutionize care at first relapse.

Key topics covered in this episode:

Tune in for this expert breakdown to navigate the new myeloma landscape with confidence.

Follow us on social media:

Subscribe for more deep dives into treatment algorithms and major conference highlights!

#OncologyBrothers #ASH2025 #MultipleMyeloma #Myeloma #SmolderingMyeloma #BispecificAntibody #Teclistamab #Daratumumab #CART

We’re kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026.

We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease.

Key topics covered in this episode:

Tune in for this dense, insightful recap and stay ahead of the curve.

Follow us on social media:

Don’t forget to subscribe for more expert analysis on treatment algorithms and major conference highlights!